Featured Article: A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer
Ovarian cancer is not often diagnosed until it has progressed to the latter stages of disease, consequently resulting in a 5-year survival rate of <50%. Recurrent ovarian cancer is typically resistant to a wide range of chemotherapy and therefore the investigation of different chemotherapeutic agents in clinical trials is of fundamental significance in trying to establish appropriate treatment for recurrent ovarian cancer.
In this research article, T. Le et al. evaluated the toxicological effects and response rate of gemcitabine/cisplatin verses gemcitabine/carboplatin for the treatment of both platinum-sensitive and platinum-resistant recurrent ovarian cancer.
Click here to access the full article.
Aims and scope
Gynecologic Oncology Research and Practice is an open access, peer-reviewed journal that publishes articles on all cancers of the female reproductive system, including cervical cancer, ovarian cancer, uterine cancer, vaginal cancer, and vulvar cancer. The journal considers articles related to the pathophysiology, prevention, diagnosis, and treatment of these cancers.
The journal aims to serve as an international platform for sharing laboratory and clinical findings by offering a high-visibility forum for new insights and discussions among scientists, physicians and oncologists.
All articles published in Gynecologic Oncology Research and Practice are now included in:
- PubMed Central
Dr Robert L Coleman, MD Anderson Cancer Center, USA
Dr Thomas J Herzog, University of Cincinnati Cancer Institute, USA
Prof Bradley J Monk, University of Arizona Cancer Center, USA
Please click here to read the Editors' Profiles
2017 Journal Metrics
59 days to first decision for reviewed manuscripts only
60 days to first decision for all manuscripts
89 days from submission to acceptance
14 days from acceptance to publication
54 Altmetric Mentions